FindTrial
Sign In

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Resected Biliary Tract Cancer Recurrence Surveillance (CCGLC-016)

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Resected Biliary Tract Cancer Recurrence Surveillance (CCGLC-016)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094232
Enrollment
Unknown
Registered
2024-12-19
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary tract cancer

Interventions

mt-ctDNA group:NA

Sponsors

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 years old and above; 2. Patients with BTC deemed operable by the hepatobiliary tumor multidisciplinary team (MDT); 3. Expected survival time of 12 weeks or more; 4. Signed informed consent form and ability to comply with the study visits and related procedures as stipulated in the protocol.

Exclusion criteria

Exclusion criteria: 1.Patients with other active tumors or severe complications; 2.Insufficient tumor tissue for MRD detection.

Design outcomes

Primary

MeasureTime frame
progression-free survival;—

Secondary

MeasureTime frame
overall survival;Changes in circulating tumor DNA (ctDNA) levels;Tumor biomarker changes;Imaging findings;—

Countries

China

Contacts

Public ContactZeyang Ding

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

zyding@tjh.timu.edu.cn+86 13407156200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026